Human papillomavirus-specific cytotoxic T lymphocytes in patients with cervical intraepithelial neoplasia grade III

Cancer Research

Volumn 57, Issue 21, 1997, Pages 4855-4861

  Nimako, Mercy ^a   Fiander, Alison N ^b   Wilkinson, Gavin W G ^a   Borysiewicz, Leszek K ^a   Man, Stephen ^a  

^a CARDIFF UNIVERSITY   (United Kingdom)

^b UNIVERSITY HOSPITAL OF WALES   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

VIRUS PROTEIN;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DIAGNOSTIC VALUE; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; MEMORY CELL; PAPILLOMA VIRUS; PREVALENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; UTERINE CERVIX CARCINOMA IN SITU; VIRUS RECOMBINANT; VIRUS TRANSFORMATION; VIRUS TYPING;

ADULT; CARCINOMA IN SITU; DNA-BINDING PROTEINS; FEMALE; HUMANS; IMMUNITY, CELLULAR; MIDDLE AGED; MONOCYTES; ONCOGENE PROTEINS, VIRAL; PAPILLOMAVIRIDAE; PHENOTYPE; REPRESSOR PROTEINS; T-LYMPHOCYTES, CYTOTOXIC; UTERINE CERVICAL NEOPLASMS;

EID: 0030728055     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (42)

1. Koutsky, L. A., Holmes, K. K., Critchlow, C. W., Stevens, C. E., Paavonen, J., Beckmann, A. M., Derouen, T. A., Galloway, D. A., Vernon, D., and Kiviat, N. B. A cohort study of the risk of cervical intraepithelial neoplasia grade 2 or grade 3 in relation to papillomavirus infection. N. Engl. J. Med., 327: 1272-1278, 1992.
2. zur Hausen, H. Viruses in human cancers. Science (Washington DC), 254: 1167-1173, 1991.
3. Bosch, F. X., Manos, M. M., Munoz, N., Sherman, M., Jansen, A. M., Peto, J., Schiffman, M. H., Moreno, V., Kurman, R., and Shah, K. V. Prevalence of human papillomavirus in cervical cancer: a worldwide perspective. J. Natl. Cancer Inst., 87: 796-802, 1995.
4. Morrison, E. A. B. Natural history of cervical infection with human papillomaviruses. Clin. Infect. Dis., 18: 172-180, 1994.
5. Farthing, A. J., and Vousden, K. H. Functions of human papilloma virus E6 and E7 oncoproteins. Trends Microbiol., 2: 170-174, 1994.
6. de Sanjose, S., Hamsikova, E., Munoz, N., Bosch, F. X., Hofmannova, V., Gili, M., Izarzugaza, I., Viladiu, P., Tormo, M. J., Moreo, P., Munoz, M. T., Ascunce, N., Tafur, L., Shah, K. V., and Vonka, V. Serological response to HPV16 in CIN III and cervical cancer patients case control studies in Spain and Colombia. Int. J. cancer. 66: 70-74, 1996.
7. Jochmus, I., and Altman, A. Immune responses to papillomavirus: prospects of an anti-HPV vaccine. Papillomavirus Rep., 4: 147-151, 1993.
8. Chen, L., Mizuno, M. T., Singhal, M. C., Hu, S. L., Galloway, D. A., Hellstrom, I., and Hellstrom, K. E. Induction of cytotoxic T lymphocytes specific for a syngeneic tumor expressing the E6 oncoprotein of human papillomavirus type 16. J. Immunol., 148: 2617-2621, 1992.
9. Meneguzzi, G., Cerni, C., Kieny, M. P., and Lathes, R. Immunization against human papillomavirus type 16 tumour cells with recombinant vaccinia viruses expressing E6 and E7. Virology, 181: 62-69, 1991.
10. Feltkamp, M. C. W., Smits, H. L., Vierboom, M. P. M., Minaar, R. M., de Jough, B. M., Drijfhout, J. W., ter Schegget, J., Melief, C. J. M., and Kast, M. W. Vaccination with cytotoxic T lymphocyte epitope-containing peptide protects against a tumor induced by human papillomavirus type 16-transformed cells. Eur. J. Immunol., 23: 2242-22449, 1993.
11. Feltkamp, M. C. W., Vreugdenhil, G. R., Vierboom, R. P. M., Ras, E., Vanderburg, S. H., Terschegget, J., Melief, C. J. M., and Kast, W. M. Cytotoxic T lymphocytes raised against a subdominant epitope offered as a synthetic peptide eradicate human papillomavirus type 16 induced tumors. Eur. J. Immunol., 25: 2638-2642, 1995.
12. Melbye, M., Palefsky, J., Gonzales, J., Ryder, L. P., Nielsen, H., Bergmann, O., Pindborg, J., and Biggar, R. J. Immune status as a determinant of human papillomavirus detection and its association with anal epithelial abnormalities. Int. J. Cancer, 46: 203-206, 1990.
13. Porreco, R., Penn, I., Droegemueller, W., Greer, B., and Makowski, E. Gynecological malignancies in immunosuppressed organ homograft recipients. Obstet. Gynecol., 45: 359-364, 1975.
14. Johnson, J. C., Burnett, A. F., Wille, G. D., Young, M. A., and Doniger, J. High frequency of latent and clinical human papillomavirus cervical infections in immunocompromised human immunodeficiency virus-infected women. Obstet. Gynecol., 79: 321-327, 1992.
15. Kast, W. M., Offringa, R., Peters, P. J., Voordouw, A. C., Meloen, R. H., van der Eb, A. J., and Melief, C. J. Eradication of adenovirus El-induced tumors by E1A-specific cytotoxic T lymphocytes. Cell, 59: 603-614, 1989.
16. Lin, Y. L., and Askonas, B. A. Biological properties of an influenza A virus-specific killer T cell clone. Inhibition of virus replication in vivo and induction of delayed-type hypersensitivity reactions. J. Exp. Med., 154: 225-234, 1981.
17. Rooney, C. M., Smith, C. A., Ng, C. Y. C., Loftin, S., Li, C. F., Krance, R. A., Brenner, M. K., and Heslop, H. E. Use of gene modified virus specific T lymphocytes to control Epstein-Barr virus-related lymphoproliferation. Lancet, 345: 9-13, 1995.
18. Walter, E. A., Greenberg, P. D., Gilbert, M. J., Finch, R. J., Watanabe, K. S., Thomas, E. D., and Riddell, S. R. Reconstitution of cellular immunity against cytomegalovirus in recipients of allogeneic bone marrow by transfer of T-cell clones from the donor. N. Engl. J. Med., 333: 1038-1044, 1995.
19. Beverley, P. C., Sadovnikova, E., Zhu, X., Hickling, J., Gao, L., Chain, B., Collins, S., Crawford, L., Vousden, K., and Stauss, H. J. Strategies for studying mouse and human immune responses to human papillomavirus type 16. Ciba Found. Symp., 187: 78-86, 1994.
20. Borysiewicz, L. K., Fiander, A., Nimako, M., Man, S., Wilkinson, G. W. G., Westmoreland, D., Evans, A. S., Adams, M., Stacey, S. N., Boursnell, M. E. G., Rutherford, E., Hickling, J. K., and Inglis, S. C. A recombinant vaccinia virus encoding human papillomavirus type 16 and type 18, E6 and E7 proteins as immunotherapy for cervical cancer. Lancet, 347: 1523-1527, 1996.
21. Cromme, F. V., Meijer, C. J. L. M., Snijders, P. L. F., Uytcrlinde, A., Kenemans, P., Helmerhorst, T., Stern, P. L., van den Brule, A. J. C., and Walboomers, J. M. M. Analysis of MHC class I and II expression in relation to presence of HPV genotypes in premalignant cervical lesions. Br. J. Cancer, 67: 1372-1380, 1993.
22. Teraski, P. I., Bernoco, D., Park, M. S., Ozturk, G., and Iwaki, Y. Microdroplet testing for HLA-A, B, C, and antigens. Am. J. Clin. Pathol., 69: 103-120, 1978.
23. Olerup, O., and Zetterquist, H. HLA-DR typing by PCR amplification with sequence-specific primers (PCR-SSP) in 2 hours: an alternative to serological DR typing in clinical pratice including donor-recipient matching in cadaveric transplantation. Tissue Antigens, 39: 225-235, 1992.
24. Wilkinson, G. W. G., and Akrigg, A. Constitutive and enhanced expression from the CMV major IE promoter in a defective adenovirus vector. Nucleic Acids Res., 20: 2233-2239, 1992.
25. Boursnell, M. E. G., Rutherford, E., Hickling, J. K., Rollinson, E. A., Munro, A. J., Rolley, N., McClean, C. S., Borysiewicz, L. K., Vousden, K., and Inglis, S. C. Construction and characterization of a recombinant vaccinia virus expressing human papillomavirus proteins for immunotherapy of cervical cancer. Vaccine, 14: 1485-1494, 1996.
26. Stauss, H. J., Davies, H., Sadovnikova, E., Chain, B., Horowitz, N., and Sinclair, C. Induction of cytotoxic T lymphocytes with peptides in vitro: identification of candidate T-cell epitopes in human papilloma virus. Proc. Natl. Acad. Sci. USA, 89: 7871-7875, 1992.
27. Ressing, M. E., van Driel, W. J., Celis, E., Sette, A., Brandt, M. P., Hartman, M., Anholts, J. D., Schreuder, G. M., ter Harmsel, W. B., Fleuren, G. J., Trimbos, B. J., Kast, W. M., and Melief, C. J. Occasional memory cytotoxic T-cell responses of patients with human papillomavirus type 16-positive cervical lesions against a human leukocyte antigen-A *0201-restricted E7-encoded epitope. Cancer Res., 56: 582-588, 1996.
28. Evans, C. W., Bauer, S., Grubert, T., Brucker, C., Baur, S., Heeg, K., Wagner, H., and Lipford, G. B. HLA-A2-restricted cytolytic T lymphocyte response to HPV proteins E6 and E7 from patients with neoplastic cervical lesions. Cancer Immunol. Immunother., 42: 151-160, 1996.
29. Martinon, F., Gomard, E., Hannoun, C., and Levy, J. P. In vitro human cytotoxic T cell responses against influenza A virus can be induced and selected by synthetic peptides. Eur. J. Immunol., 20: 2171-2176, 1990.
30. Yee, C., Gilbert, M. J., Riddell, S. R., Brichard, V. G., Fefer, A., Thompson, J. A., Boon, T., and Greenberg, P. D. Isolation of tyrosinase specific CD8(+) and CD4(+) T cell clones from the peripheral blood of melanoma patients following in vitro stimulation with recombinant vaccinia virus. J. Immunol., 157: 4079-4086, 1996.
31. Bauer, H. M., Ting, Y., and Greer, C. E. Genital human papillomavirus infection in female university students as determined by a PCR-based method. J. Am. Med. Assoc., 265: 472-477, 1991.
32. Borysiewicz, L. K., Morris, S., Page, J. D., and Sissons, J. G. P. Requirements for in vitro generation of human cytomegalovirus specific cytotoxic T cell lines. Eur. J. Immunol., 13: 804-809, 1983.
33. Borysiewicz, L. K., Hickling, J. K., Graham, S., Sinclair, J., Cranage, M. P., Smith, G. L., and Sissons, J. G. P. Human cytomegalovirus specific cytotoxic T cells recognise the 72kD immediate early protein and glycoprotein B in recombinant vaccinia viruses. J. Exp. Med., 168: 919-931, 1988.
34. Rickinson, A. B., Moss, D. J., and Wallace, L. E. Long term T-cell-mediated immunity to Epstein-Barr virus. Cancer Res., 41: 4216-4221, 1981.
35. Tay, S. K., Jenkins, D., Maddox, P., Campion, M., and Singer, A. Subpopulations of Langerhans' cells in cervical neoplasia. Br. J. Obstet. Gynaecol., 94: 10-15, 1987.
36. Tay, S. K., Jenkins, D., Maddox, P., and Singer, A. Lymphocyte phenotypes in cervical intraepithelial neoplasia and human papillomavirus infection. Br. J. Obstet. Gynaecol., 94: 16-21, 1987.
37. Huang, A. Y. C., Golumbek, P., Ahmadzadeh, M., Jaffee, E., Pardoll, D., and Levitsky, H. Role of bone marrow derived cells in presenting MHC class I restricted tumor antigens. Science (Washington DC), 264: 961-965, 1994.
38. Toes, R. E. M., Offringa, R., Blom, R. J. J., Melief, C. J. M., and Kast, W. M. Peptide vaccination can lead to enhanced tumor growth through specific T cell tolerance induction. Proc. Natl. Acad. Sci. USA, 93: 7855-7860, 1996.
39. Ellis, J. R., Keating, P. J., Baird, J., Hounsell, E. F., Renouf, D. V., Rowe, M., Hopkins, D., Duggan-Keen, M. F., Bartholomew, J. S., Young, L. S., and Stern, P. L. The association of an HPV16 oncogene variant with HLA-B7 has implications for vaccine design in cervical cancer. Nat. Med., 1: 464-470, 1995.
40. Thomson, S. A., Elliott, S. L., Sherritt, M. A., Sproat, K. W., Coupar, B. E. H., Scalzo, A. A., Forbes, C. A., Ladhams, A. M., Mo, X. Y., Tripp, R. A., Doherty, P. C., Moss, D. J., and Suhrbier, A. Recombinant polyepitope vaccines for the delivery of multiple CD8 cytotoxic T cell epitopes. J. Immunol., 157: 822-826, 1996.
41. Evans, E. M., Man, S., Evans, A. S., and Borysiewicz, L. K. Infiltration of cervical cancer tissue with human papilloma virus-specific CTLs. Cancer Res., in press, 1997.
42. Fiander, A., Adams, M., Evans, A. S., Bennett, A. J., and Borysiewicz, L. K. Immunocompetent for immunotherapy? A study of the immunocompetence of cervical cancer patients. Int. J. Gynecol. Cancer, 5: 438-442, 1995.